CTI wins over FDA to claim early review of myelofibrosis drugShares in US biotech CTI BioPharma have shot up after the FDA agreed to an accelerated review early Share XCTI wins over FDA to claim early review of myelofibrosis drughttps://pharmaphorum.com/news/cti-wins-over-fda-to-claim-early-review-of-myelofibrosis-drug/
Sobi stays on its acquisitive streak with $915m Dova dealSweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover Share XSobi stays on its acquisitive streak with $915m Dova dealhttps://pharmaphorum.com/news/sobi-stays-on-its-acquisitive-streak-with-915m-dova-deal/
Shionogi’s Mulpleta gets FDA green light for patients with liver diseaseThe US drug regulator has approved Mulpleta (lusutrombopag) as a treatment for thrombocytopenia in certain patients with chronic Share XShionogi’s Mulpleta gets FDA green light for patients with liver diseasehttps://pharmaphorum.com/news/shionogis-mulpleta-gets-fda-green-light-for-patients-with-liver-disease/
